ETON insider transaction filings
Eton Pharmaceuticals, Inc. — 36 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-20. Screen ETON transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-20 | 4 | BRYNJELSEN SEAN — President & CEO, Director | Sale (S): 8,978 @ $62.65 · Sale (S): 47,307 @ $60.17 · Sale (S): 36,373 @ $61.11 · Sale (S): 7,342 @ $62.12 | EDGAR |
| 2026-08-04 | 4 | CASAMENTO CHARLES J — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-08-04 | 4 | Erdogan-Trinkaus Ipek — Chief Commercial Officer | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2026-08-04 | 4 | Matthews Judith M. — Chief Financial Officer | Grant/award (A): 32,246 (derivative) @ $0 | EDGAR |
| 2026-08-04 | 4 | Krempa David — Chief Business Officer | Grant/award (A): 128,985 (derivative) @ $0 | EDGAR |
| 2026-08-04 | 4 | BRYNJELSEN SEAN — President & CEO, Director | Grant/award (A): 128,985 (derivative) @ $0 | EDGAR |
| 2026-08-04 | 4 | MAIER PAUL V — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-08-04 | 4 | Adams Jennifer McKie — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-08-04 | 4 | RIEDEL NORBERT G — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-07-17 | 4/A | Opaleye Management Inc. — 10% owner | Sale (S): 15,000 @ $37.54 · Sale (S): 13,315 @ $37.54 | EDGAR |
| 2026-07-16 | 4 | Opaleye Management Inc. — 10% owner | Sale (S): 15,000 @ $37.54 · Sale (S): 13,315 @ $37.54 | EDGAR |
| 2026-07-14 | 4 | BRYNJELSEN SEAN — President & CEO, Director | Option exercise (M): 27,500 · Option exercise (M): 200,000 @ $1.37 · Option exercise (M): 27,500 (derivative) @ $0 · Option exercise (M): 200,000 (derivative) @ $0 | EDGAR |
| 2026-07-13 | 4 | Krempa David — Chief Business Officer | Option exercise (M): 10,000 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-07-07 | 4 | Opaleye Management Inc. — 10% owner | Sale (S): 65,000 @ $37.39 · Sale (S): 25,000 @ $37.39 · Sale (S): 10,000 @ $38 · Sale (S): 20,000 @ $38.37 · Sale (S): 6,685 @ $38.37 | EDGAR |
| 2026-06-30 | 4 | Krempa David — Chief Business Officer | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Adams Jennifer McKie — Director | Option exercise (M): 50,000 @ $3.78 · Sale (S): 50,000 @ $32.48 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | BRYNJELSEN SEAN — President & CEO, Director | Sale (S): 119,852 @ $31.88 · Sale (S): 148 @ $32.67 | EDGAR |
| 2026-05-27 | 4 | Krempa David — Chief Business Officer | Option exercise (M): 30,591 @ $3.58 · Sale (S): 32,963 @ $33.22 · Sale (S): 9,315 @ $33.88 · Sale (S): 519 @ $35 · Option exercise (M): 25,000 @ $1.38 · Option exercise (M): 12,524 @ $1.37 · +9 more | EDGAR |
| 2026-04-22 | 4 | RIEDEL NORBERT G — Director | Option exercise (M): 12,500 @ $7.31 · Option exercise (M): 19,655 @ $8.61 · Option exercise (M): 12,500 (derivative) @ $0 · Option exercise (M): 19,655 (derivative) @ $0 | EDGAR |
| 2026-02-05 | 4 | RIEDEL NORBERT G — Director | Option exercise/expiry (X): 30,000 @ $4.42 · Option exercise/expiry (X): 30,000 (derivative) @ $0 | EDGAR |
| 2026-01-14 | 4 | Adams Jennifer McKie — Director | Grant/award (A): 12,196 (derivative) @ $0 · Grant/award (A): 7,757 (derivative) @ $0 | EDGAR |
| 2026-01-14 | 4 | Erdogan-Trinkaus Ipek — Chief Commercial Officer | Grant/award (A): 40,655 (derivative) @ $0 · Grant/award (A): 25,856 (derivative) @ $0 | EDGAR |
| 2026-01-14 | 4 | Krempa David — Chief Business Officer | Tax withholding (F): 1,942 @ $15.62 · Grant/award (A): 40,655 (derivative) @ $0 · Grant/award (A): 25,856 (derivative) @ $0 | EDGAR |
| 2026-01-14 | 4 | Gruber James R. — Chief Financial Officer | Tax withholding (F): 2,293 @ $15.47 · Grant/award (A): 40,655 (derivative) @ $0 · Grant/award (A): 25,856 (derivative) @ $0 | EDGAR |
| 2026-01-14 | 4 | BRYNJELSEN SEAN — President & CEO, Director, 10% owner | Tax withholding (F): 5,015 @ $15.39 · Grant/award (A): 158,046 (derivative) @ $0 · Grant/award (A): 100,517 (derivative) @ $0 | EDGAR |
| 2026-01-14 | 4 | MAIER PAUL V — Director | Grant/award (A): 12,196 (derivative) @ $0 · Grant/award (A): 7,757 (derivative) @ $0 | EDGAR |
| 2026-01-14 | 4 | RIEDEL NORBERT G — Director | Grant/award (A): 12,196 (derivative) @ $0 · Grant/award (A): 7,757 (derivative) @ $0 | EDGAR |
| 2026-01-14 | 4 | CASAMENTO CHARLES J — Director | Grant/award (A): 12,196 (derivative) @ $0 · Grant/award (A): 7,757 (derivative) @ $0 | EDGAR |
| 2025-12-12 | 4 | Erdogan-Trinkaus Ipek — Chief Commercial Officer | Tax withholding (F): 85 @ $16.90 | EDGAR |
| 2025-12-12 | 4 | Krempa David — Chief Business Officer | Tax withholding (F): 6,264 @ $17 · Grant/award (A): 5,300 (derivative) @ $0 | EDGAR |
| 2025-12-12 | 4 | Gruber James R. — Chief Financial Officer | Tax withholding (F): 4,542 @ $16.99 · Grant/award (A): 5,502 (derivative) @ $0 | EDGAR |
| 2025-12-12 | 4 | BRYNJELSEN SEAN — President & CEO, Director, 10% owner | Tax withholding (F): 6,732 @ $16.83 | EDGAR |
| 2025-08-20 | 4 | Gruber James R. — Chief Financial Officer | Sale (S): 39,082 @ $16.16 · Sale (S): 2,631 @ $16.02 | EDGAR |
| 2025-06-16 | 4 | Krempa David — Chief Business Officer | Sale (S): 16,977 @ $14.92 · Sale (S): 6,800 @ $14.77 · Sale (S): 10,223 @ $14.73 | EDGAR |
| 2025-06-12 | 4 | Opaleye Management Inc. — 10% owner | Purchase (P): 5,000 @ $15.82 · Purchase (P): 2,930 @ $15.82 | EDGAR |
| 2025-06-05 | 4 | BRYNJELSEN SEAN — President & CEO, Director, 10% owner | Sale (S): 60,945 @ $17.38 · Sale (S): 8,655 @ $18.38 · Sale (S): 400 @ $19.02 · Sale (S): 70,000 @ $17 · Sale (S): 70,000 @ $16.81 | EDGAR |
Recent 8-K events — Eton Pharmaceuticals, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-05 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-04 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-07-29 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-09 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-19 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-01 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-27 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-16 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ETON returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →